Rofleponide

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H34F2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9IQ7GVL3E, chemically known as 6 alpha, 9-difluoro-11 beta, 16 alpha, 17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (r)-16,17-acetal with butyraldehyde. but generally known as rofleponide, which bears US NIH Compound Identifier 3055174. European Medicines Agency schedules Rofleponide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10357MIG. The term ROFLEPONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ROFLEPONIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rofleponide under HS 29372900 and SITC 54153. As of Q4 2014, ROFLEPONIDE remains the US FDA Preferred Term for this commodity. Rofleponide bears US NLM identifiers UMLS ID C2699093 and NCI Concept Code C77006. SMILES: FC12C(C3C(C4(OC(OC4C3)CCC)C(=O)CO)(CC1O)C)CC(F)C1=CC(=O)CCC21C.